Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation [PDF]
Journal of Pharmaceutical Analysis, 2023 Given that impurities may affect the quality and safety of drug products, impurity identification and profiling is an integral part of drug quality control and is particularly important for newly developed medications such as solriamfetol, which is used ...
Yousef Al-Ebini +2 more
exaly +7 more sources
Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial [PDF]
Frontiers in MedicineIntroductionWake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA).
Fen Wang +7 more
doaj +3 more sources
Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. [PDF]
PLoS ONEPurposeExcessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents.
Lingling Wu, Kaijian Zhu
doaj +2 more sources
Pharmacological and non-pharmacological methods of inducing wakefulness activate distinct neural populations in the mouse brain. [PDF]
PLoS BiologyA large body of data indicate that the aminergic, cholinergic and hypocretin/orexin neurons are responsible for inducing wakefulness. However, recent data showed that other systems might also play a key role.
Renato Maciel +8 more
doaj +2 more sources
Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]
BMC NeurologyBackground As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan +5 more
doaj +2 more sources
Pharmacology Research and Perspectives, 2021 Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief +2 more
exaly +2 more sources
Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders [PDF]
Clinical Pharmacology: Advances and ApplicationsKatyayini Aribindi,1 Tanwe C Shende,1,2 Timothy E Albertson11Department of Internal Medicine – Division of Pulmonary, Critical Care & Sleep Medicine, University of California – Davis, Sacramento, CA, USA; 2Department of Medicine, Veterans Affairs ...
Aribindi K, Shende TC, Albertson TE
doaj +2 more sources
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis [PDF]
Nature and Science of Sleep, 2023 Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S +7 more
doaj +2 more sources
Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin +11 more
doaj +2 more sources
Comparative potential for generating spontaneous signals for abuse and dependence among drugs used for attention deficit hyperactivity disorder: A disproportionality analysis in VigiBase®. [PDF]
Gen PsychiatrABSTRACT Background The comparative liability for abuse and dependence of drugs used for attention deficit hyperactivity disorder (ADHD) has been poorly explored so far. Aims To evaluate the relative potential of medications used for ADHD for generating spontaneous reports of abuse and dependence in international pharmacovigilance data.
Jouanjus E +4 more
europepmc +2 more sources